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ABSTRACT 
The cellular prion protein (PrPC) is best known for its misfolded disease-causing 
conformer, PrPSc. Because the availability of PrPC is often limiting for prion propagation, 
understanding its regulation may point to possible therapeutic targets. We sought to 
determine to what extent the human microRNAome is involved in modulating PrPC levels 
through direct or indirect pathways. We probed PrPC protein levels in cells subjected to a 
genome-wide library encompassing 2019 miRNA mimics using a robust time-resolved 
fluorescence-resonance screening assay. Screening was performed in three human 
neuroectodermal cell lines: U-251 MG, CHP-212 and SH-SY5Y. The three screens yielded 
17 overlapping high-confidence miRNA mimic hits, 13 of which were found to regulate PrPC 
biosynthesis directly via binding to the PRNP 3’UTR, thereby inducing transcript 
degradation. The four remaining hits (miR-124-3p, 192-3p, 299-5p and 376b-3p) did not bind 
either the 3’UTR or CDS of PRNP, and were therefore deemed indirect regulators of PrPC. 
Our results show that multiple miRNAs regulate PrPC levels both directly and indirectly. 
These findings may have profound implications for prion disease pathogenesis and 
potentially also for their therapy. Furthermore, the possible role of PrPC as a mediator of Aβ 
toxicity suggests that its regulation by miRNAs may also impinge on Alzheimer’s disease.   
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INTRODUCTION 
Prion diseases are characterized by misfolding and aggregation of the cellular prion 
protein (PrPC) into its pathogenic conformer, PrPSc (42). Despite significant advances in 
exposing the physiological roles of PrPC and in elucidating mechanisms underlying PrPSc-
induced toxicity, the molecular machinery controlling spatiotemporal PrPC expression 
remains unexplored. 
Over the past decade, microRNAs (miRNA) have emerged as important biomarkers and 
micro-modulators of numerous biological processes ranging from development to disease 
(19). These roughly 22 nucleotide non-coding RNAs predominantly regulate protein 
expression levels post-transcriptionally by repressing and/or degrading an estimated 60% of 
all human protein-coding transcripts (16). miRNAs function by associating with Argonaute 
(AGO) proteins to form a mature miRNA-induced silencing complex (miRISC). While four 
human AGO proteins have been described, only AGO2 possesses endonucleolytic activity 
(31). miRNAs guide the miRISC to targets by typically binding their 2-8 nucleotide “seed 
sites” to complementary mRNA 3’ untranslated regions (3’UTRs) (22). Comprehensive 
analysis of miRNA interaction sites in human brains using Argonaute cross-linking 
immunoprecipitation (AGO-CLIP) has revealed that 41% of these sites reside in 3’UTRs, 
while coding sequences (CDS), intronic regions and 5’ untranslated regions (5’UTR) make 
up the other 40, 15 and 1% respectively (9). 
Several miRNAs, most notably miR-124-3p, miR-146a-5p and miR-342-3p, have been 
found to become consistently deregulated following prion infection in GT1-7 neuronal cells 
(7), RML inoculation in mice (39, 40), scrapie infection in sheep (41), BSE infection in 
macaques (33) and sporadic Creutzfeldt-Jakob disease (sCJD) in humans (25). These 
miRNAs also display similar spatiotemporal expression patterns during prion disease 
pathogenesis (8, 27) and in sCJD subtypes (23), implying that mechanisms of deregulation 
may be conserved across species. Intriguingly, miR-124-3p, which is highly expressed in 
almost all brain regions (44), has also been found to be downregulated in the brains of 
patients suffering from Alzheimer’s (24) and Huntington’s disease (18). These data 
collectively qualify miRNAs as potential biomarkers and as possible regulators of the 
pathogenic process in transmissible spongiform encephalopathies (TSE). It has also been 
reported once (but never confirmed) that human PrPC binds AGO, and in doing so promotes 
the formation and stabilization of miRISC (17). However, it remains unknown to what extent, 
miRNAs might play a part in regulating PrPC expression levels. As suppression of PrPC by 
shRNA can abrogate PrPSc accumulation and prolongs survival of scrapie-infected mice 
(37), identification of endogenous PrPC modulators may provide a therapeutic avenue for 
TSEs. 
Several miRNA target prediction tools exist that calculate likeliness of miRNA binding to 
transcripts through assessing their thermodynamic stability and conserved seed region 
complementarity in 3’UTR (1) and CDS (38). Yet, these estimates remain tentative due to 
their high degree of false positives. AGO-CLIP offers a more biologically accurate 
compendium of miRNA-bound target sites. However, as these data are predominantly 
generated via AGO2 immunoprecipitation, the recovered hits correspond mostly to 
endonucleolytically cleaved transcripts (31), whereas the pleiotropic interplay between other 
AGO proteins is not reflected in CLIP data (43). Furthermore, miRNA-AGO associations do 
not necessarily imply functional downstream effects. Accordingly, a comparison of miRNA 
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transfection and AGO-CLIP data revealed an overlap between miRNA targets detected by 
the two approaches, but found that CLIP was not strongly predictive of target expression 
changes (45). Cell-based screenings can address the limitations of target detection 
techniques by assessing functionality of canonical, non-canonical and indirect regulators. 
The current study aims to examine the degree to which the human microRNAome affects 
PrPC expression, and determine whether PrPC-regulating miRNAs function through direct or 
indirect pathways. Towards this goal, we developed a robust high-throughput arrayed 
screen, employing a genome-wide miRNA library. This exploratory approach was able to 
exhaustively analyze miRNA-induced changes in PrPC, some of which were previously 
predicted by target interaction estimates whereas others are entirely novel. These findings 
may acquire medical significance in view of the requirement for PrPC in development of prion 
diseases (12, 13) and its presumed, albeit controversial, role in mediating Aβ toxicity in 
Alzheimer’s disease (14, 21). 
 
METHODS 
Cell lines 
A homozygous frameshift mutation was generated in the PRNP locus of SH-SY5Y 
(ATCC) using the CRISPR-Cas9 system to delete the second adenine in the third codon of 
the PRNP CDS (chr20: 4,699,229), located in exon 2. This was achieved by designing a 
sgRNA that bound in close proximity to the PRNP start codon. This sgRNA was cloned 
into a MLM3636 expression vector and transfected into SH-SY5Y wt cells alongside a Cas9-
2A-EGFP plasmid. 48h after transfection, single EGFP-positive cells were sorted into a 96 
well plate by single cell fluorescence-activated cell sorting. Individual clones were expanded 
for four weeks and screened for PRNP-/-. Clones were characterized by blunt-end PCR 
insertion of PRNP fragments into TOPO vectors. Sanger sequencing (Fig. S1) revealed that 
a double strand break and subsequent non-homologous end joining had induced a 
frameshift and a premature stop codon, resulting in a functional PrPC knockout mutant. The 
full-length 765bp linearized CDS region of mouse Prnp, under the control of a CMV 
promotor, was stably transfected and randomly integrated into these PrPC knockout cells. 
Following antibiotic selection, a single clone, designated SH-SY5Y M4, was expanded on 
the basis of high PrPC expression levels. 
SH-SY5Y M4 and U-251 MG (Merck) cells were cultured in OptiMEM supplemented with, 
1% GlutaMAX (GM), 1% MEM Non-Essential Amino Acids, 1% Penicillin/Streptomycin (PS) 
(Thermo Fisher) and 10% FBS (Clontech). CHP-212 were cultured in a 1:1 ratio of EMEM 
(ATCC) to Ham’s F12 Nutrient Mixture (Thermo Fisher) supplemented with 10% FBS and 
1% PS. HEK-293T (ATCC) were cultured in DMEM (Thermo Fisher) supplemented with 10% 
FBS, 1% GM and 1% PS. All cell lines were grown in 150-cm2 Corning cell culture flasks 
(Merck), counted using Trypan Blue (Thermo Fisher) in a TC20 Automated Cell Counter 
(Bio-Rad) and seeded in absence of antibiotics during experimentation. 
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Screen Workflow 
2019 mirVana miRNA mimics or analogous inhibitors (Ambion) were printed as triplicates 
in disparate locations across 24 white CulturPlate-384 (PerkinElmer) alongside Silencer 
Select human PRNP / mouse Prnp-targeting (Ambion) positive control and AllStars Negative 
Control (Qiagen) siRNAs (44 per plate: 22 in outer- and 22 in central wells). Printing was 
performed using an Echo 555 acoustic dispenser (Labcyte) to obtain final concentrations of 
20nM for mimics and control siRNAs or 60nM for inhibitors per well. All following dispensing 
steps were carried out using peristaltic dispensing technology on the MultifloFX (Biotek) with 
cassettes as indicated. Printed libraries were reverse transfected into cells by first 
dispensing 5uL RNAiMAX (0.3% final) (Thermo Fisher) diluted in PS-free media using a 1uL 
cassette. Plates were centrifuged and seeded with 25uL of 4000 SH-SY5Y M4, 5000 CHP-
212 or 6000 U-251 MG per well using a 5uL cassette. 
Following a 72-hour incubation period at 37°C, media was removed by turning the plate 
upside-down and 10uL of lysis buffer (0.5% Na deoxycholate, 0.5% Triton X, supplemented 
with cOmplete Mini Protease Inhibitors and 0.5% BSA (Merck)) was dispensed per well. 5uL 
(2.5nM final) POM2 or POM19 (made in-house), coupled to Europium (Eu), as previously 
described (4), and diluted in 1X Lance Detection Buffer (Perkin Elmer) was dispensed for U-
251 MG and CHP-212 or SH-SY5Y M4 cells respectively. 5uL (5nM final) POM1 conjugated 
to Allophycocyanin (APC) was successively added per well for all cell types screened. TR-
FRET readout was performed after a 12-hour 4°C incubation using an EnVison 2105 
Multimode Plate Reader (PerkinElmer) with previously defined measurement parameters (4). 
 
Quantitative PCR 
Candidate mimic PRNP mRNA levels were assessed in a follow-up U-251 MG screen. 
Samples were identically processed up to the point of media removal, after which a 3:1 
mixture of TRIzolLS (Thermo Fisher) to media was applied to wells and mRNA was 
extracted according the manufacturers’ protocol. QuantiTect Reverse Transcription Kit 
(Qiagen) was used for cDNA synthesis and qPCR was performed using FastStart Universal 
SYBR Green Master (Rox) (Merck). Candidate mimics were run in biological triplicates and 
assessed for PRNP mRNA levels using GUSB, TBP and ACTB as housekeeping genes for 
sample normalization. HMGA2 mRNA normalized to ACTB was used as a post-inhibitor 
screen quality control assessment to test library efficacy, using let-7d-5p inhibitor as a 
presumptive positive regulator of HMGA2. All qPCR samples were run in technical triplicates 
in white Hard-Shell 96-Well PCR Plates (Bio-Rad) using the following primer pairs: 
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PRNP (NM_000311.4):  For: GACCGAGGCAGAGCAGTCAT  
Rev: AGTGTTCCATCCTCCAGGCTTC 
ACTB (NM_001101.3):  For: ACAGAGCCTCGCCTTTGCC 
Rev: AGCGCGGCGATATCATCATCC 
GUSB (NM_000181.3):  For: GACACGCTAGAGCATGAGGG 
Rev: GGGTGAGTGTGTTGTTGATGG 
TBP (NM_003194.4):  For: CCCGAAACGCCGAATATAATCC 
Rev: AATCAGTGCCGTGGTTCGTG 
HMGA2 (NM_003483.4):  For: CACTTCAGCCCAGGGACAAC 
Rev: CTCACCGGTTGGTTCTTGCT 
 
Cell Viability 
To assess miRNA-induced alterations in cell viability, we used AllStars Hs Cell Death 
Control siRNA (Qiagen) as a positive control for candidate mimics in a follow-up U-251 MG 
screen. After 72h incubation and media removal, 10uL fresh media and 10uL CellTiter-Glo 
2.0 (Promega) were added per well. Samples were incubated for 20 min at room 
temperature prior to performing an Ultra-Sensitive luminescence readout on an EnVision 
reader at 0mm measurement height and 0.3s integration time.  
 
Quality Control 
Following TR-FRET readout, FRET data from each 384-well plate was inspected for the 
presence of systematic and random errors, e.g. temperature-induced plate gradients, 
dispensing patterns, or problems while printing constructs into wells. We used the open-
source Python3 software tool HTS (High Throughput Screening) for data handling, screen 
quality control, statistical analysis and reporting of per-well measurement data. Source code, 
installation manual, tutorials and data examples are available via elkeschaper.github.io/hts. 
HTS provides standard screening parameters in an automated and highly standardized 
manner. To comply with reproducible research standards, code, explanations, and analyses 
are all provided in one notebook report. In particular, the following readouts were computed 
with HTS: Net-FRET calculations and heat map visualizations for controls and samples, TR-
FRET channel as well as cell viability heat maps, histograms and smoothened histograms 
for visualization of controls and samples, Z’-factor and SSMD calculations, row / column 
effects.  
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Data Analysis 
Net FRET calculations and blank subtractions were performed as previously described 
(4) per plate for each mimic and inhibitor screen. Z’-Factors (Z’) were calculated across all 
24 plates per screen using central controls. Sample SSMDs were derived from biological 
triplicates and central negative control mean and standard deviation values across four 
plates, amongst which replicas were printed. Mimic screening hit calling criteria were set at 
≥5, ≤-5 for U-251 MG and ≥3, ≤-3 for both CHP-212 and SH-SY5Y M4. Inhibitor screen hit 
calling criteria were set at ≥1.5, ≤-1.5 for U-251 MG and CHP-212 due to overall low SSMD 
scores. Negative and positive controls from TR-FRET, cell viability and qPCR assays were 
set at 100% and 0% respectively. Samples were normalized to this range by feature scaling. 
An arbitrary 10% cutoff above or below the negative control was selected as the determinant 
for altered PrPC, cell viability or PRNP mRNA levels. An unpaired two-tailed parametric t-test 
was used for calculating significance between samples for the reporter assays. 
 
Reporter Construction 
The wt PRNP 3’UTR and 9 mutant forms thereof (Tab.S1) were cloned into pmirGLO 
Dual-Luciferase miRNA Target Expression Vector (Promega) multiple cloning sites, 
downstream of firefly luciferase. Incorporation was achieved by simultaneously cloning 
various combinations of three gBlocks (IDT) into the cleaved multiple cloning site using 
Gibson Assembly Master Mix (NEB). Each mutant construct was designed to harbor two 
single nucleotide substitutions separated by a single unaltered nucleotide in the prospective 
single- or double binding site/s of the 3’UTR (30). Mimic hit site selection was based on 
TargetScan7.2 in silico predicted interactions. A reporter harboring the wt PNRP CDS was 
constructed by PCR-amplifying the insert from primary human myoblast gDNA and cloning it 
in-frame into the multiple cloning site of pmirGLO. Plasmid assembly was confirmed by XmnI 
(NEB) restriction digestion and insert sequencing using the following primers: 
Seq-3'UTR Rev2: GCAATTTACTTTTCAGCTGCC 
Seq-3'UTR For2: CTCTGGCTCCTTCAGCAGCTAG 
Seq-3'UTR For3: GGAGGCAACCTCCCATTTTAGATG 
Seq-CDS Rev1: CTGCCGAAATGTATGATGGG 
Seq-CDS For2: GTGGCTGGGGTCAAGGAG 
 
Reporter Assessment 
Plasmid reporters (20ng) and their corresponding mimics (20nM final) were printed in 
white CulturPlate-384 and reverse co-transfected into HEK-293T using Lipofectamine 2000 
(Thermo Fisher) (0.3% final). Following a 37°C 48-hour incubation period, 30uL of each 
Dual-Glo Luciferase Assay System (Promega) reagent was sequentially added per well and 
incubated at RT for 20min prior to Ultra-Sensitive luminescence readout. Firefly luciferase 
signals were subsequently divided by Renilla luciferase signals for each well. 
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Western Blotting 
10-30µg of BCA-defined cell lysate was boiled at 95°C in NuPAGE LDS (Thermo Fisher) 
supplemented with 100mM DTT (Roche). Samples were loaded on NuPAGE 4-12% Bis-Tris 
gels and transferred to PVDF membranes via an iBlot 2 (Thermo Fisher). Membranes were 
blocked in 5% SureBlock (LuBio Science) and stained using POM1 or mouse anti-actin 
(Chemicon). HRP-conjugated goat anti-mouse (Jackson) was used as a secondary antibody 
and Immobilon Crescendo (Merck) was used for imaging. 
 
RESULTS 
High-Throughput Screen Reliably Detects PrPC 
To identify miRNAs regulating PrPC, we performed a genome-wide human miRNA 
screen. We assessed PrPC levels from cell lysates in single wells using a time-resolved 
fluorescence resonance energy transfer (TR-FRET) readout as described (4). This allowed 
high-throughput arrayed screening of the entire currently available human miRNA repertoire 
(miRBase v.21), consisting of 2’019 mimics and 2’019 corresponding inhibitors. Screening 
was performed using U-251 MG glioblastoma, CHP-212 neuroblastoma and SH-SY5Y M4 
neuroblastoma human cell lines (Fig. 1A). Cell lines were selected based on high PrPC 
expression, as revealed by western blot (Fig. S2A) and TR-FRET (Fig. S2B). SH-SY5Y M4, 
a PRNP-/- line overexpressing the mouse Prnp CDS (see Methods), was used for the 
selective interrogation of non-3’UTR regulating miRNAs. Overlap of miRNA-mediated PrPC 
regulation in multiple cell lines allowed us to identify high-confidence hits that may be 
universally functional. 
As RNA interference (RNAi) screens are often hampered by poor reproducibility (5), we 
set out to develop a highly robust assay by optimizing sample and control distributions, 
library concentration, transfection reagent concentration, cell number, reaction volumes, 
incubation duration, lytic buffer composition and fluorophore-coupled antibody concentration. 
In order to minimize effects of temperature-induced gradients observed in cell-based 
screens (26), we implemented a media removal step at 72 hours (see Methods). We found 
that the incorporation of this step strongly reduced replicate variability (Fig. S3). This 
observation indicated that pre-media removal artefacts had primarily resulted from 
volumetric well-to-well disparities. No systemic intra- or inter-plate gradients were observed 
for any screen. However, plate-well series plots assessing row effects revealed small, albeit 
consistently disproportionate signals among outer, but not central control wells. Outer control 
wells were therefore excluded from all analyses. 
PRNP/Prnp-targeting siRNA positive controls and non-targeting siRNA negative controls 
dispersed throughout each plate served as a screening quality benchmark. U-251 MG mimic 
screening yielded the most pronounced separation of controls (Fig. 1B), as revealed by a 
high Z-factor (Z’: 0.453) across 24 plates. In contrast, CHP-212 and SH-SY5Y M4 screens 
only displayed poor (Z’: -0.403) and marginal (Z’: 0.072) qualities respectively (46). Mimic 
replicates showed a robust correlation for U-251 MG (R2 mean: 0.65) and CHP-212 (R2 
mean: 0.52), which was not the case for SH-SY5Y M4 (R2 mean: 0.22) (Fig. S2C). miRNA 
inhibitors, while generating similar Z’ for U-251 MG: 0.396 and CHP-212: -0.346 (Fig. S4B) 
did not affect PrPC expression levels (Fig. S4C). Notably, low CHP-212 Z-factors, stemming 
from high control signal variabilities, may have been imparted by cell growth saturation. 
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Identification of 19 Overlapping Candidate Mimics 
In order to highlight differences in sample reproducibility, denoted by strictly standardized 
mean difference (SSMD) (47), and biological effect sizes, denoted by log2 fold change, 
amongst cell lines, we visualized screening data using dual-flashlight plots (Fig. 2A and Fig. 
S5A). Hit selection was performed by overlaying SSMDs from CHP-212 or SH-SY5Y M4 
with U-251 MG screens. We applied SSMDs set at extremely strong cutoffs (≥5, ≤-5) for U-
251 MG, and very strong cutoffs (≥3, ≤-3) (48) for CHP-212 and SH-SY5Y M4 cells. This 
yielded a total of 12 candidate mimics from CHP-212 screen overlaps (blue crosses) and 7 
candidate mimics from SH-SY5Y M4 screen overlaps (red crosses) (Fig. 2B). Mimic screen 
datasets displaying replicate Net FRET, SSMD, log2 fold change, p-value, miRNA name and 
sequence are listed in Tab.S2. Intersection of CHP-212 and SH-SY5Y M4 SSMDs shows 
that this strategy would have called only 3 out of the 19 candidates (Fig. 2C). However, as 
CHP-212 produced a poor Z’ and SH-SY5Y M4 harbored no PRNP 3’UTR, we opted to 
utilize a more reliable hit-calling strategy by contrasting screens only to U-251 MG. 
Inhibitor screening on the other hand, produced no overlaps between cell lines, even 
when setting low SSMD (≥1.5, ≤-1.5) cutoff criteria (Fig. S5B). Moreover, no inhibitor 
generated SSMDs ≤-3 or ≥3 in any individual cell line. Inhibitor screen datasets are shown in 
Tab.S3. We assessed whether the absence of inhibitor effects was due to a lack of library 
functionality by transfecting U-251 MG with the library-sourced let-7d-5p inhibitor, a known 
regulator of HMGA2 (36). A statistically significant upregulation of HMGA2 expression was 
observed at all concentrations (Fig. S4A), indicating that our inhibitor library was functional. 
These findings suggest a potential compensatory role in the regulation of PrPC expression 
by endogenous miRNAs, which could be overcome by simultaneous inhibition of all 
functionally redundant miRNAs. Alternatively, it is likely that U-251 MG and CHP-212 
express insufficient quantities of endogenous PrPC-regulating miRNAs. 
While the majority of mimics displayed consistent PrPC down- or up-regulation, three 
candidates exhibited divergent PrPC regulatory effects in different cell lines (Fig. 2B). Each of 
these opposing effects was attributed to a mimic-induced altered cell number in a follow-up 
viability assessment (Fig. S6B). For example, miR-342-5p was found to increase cell viability 
in U-251 MG, which contrarily may have resulted in death of the already growth saturated 
CHP-212 cells. In contrast, miR-148b-3p, which was found to increase viability of U-251 MG 
cells while simultaneously eliciting PrPC downregulation by targeting the PRNP 3’UTR could 
exclusively be detected in SH-SY5Y M4 when contrasted to U-251 MG (Fig. 2B). By this 
standard, a majority of miRNA mimic candidates eliciting an effect on PrPC via the PRNP 
3’UTR would be detectable only in U-251 MG-CHP-212 overlaps. 
 
Hits Predominantly Reduce Steady State PRNP mRNA Levels 
We first sought to determine whether the regulatory actions of our candidate mimics on 
PrPC were independent of any miRNA-induced alterations in cell growth. To do so, we 
transfected mimics into U-251 MG alongside scrambled negative- as well as cell death-
inducing positive control siRNAs, and assessed changes in viability. Based on our cutoff 
criteria, no miRNAs decreased cell viability whereas six out of the 19 mimic candidates 
increased cell viability (Fig. S6B). However, out of these 6 mimics only miR-342-5p and miR-
4802-5p displayed a concomitant PrPC increase (Fig. S6A). These two mimic candidates are 
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therefore likely to increase PrPC levels due to increased cell viability. The remaining 17 
mimics were considered high-confidence hits regulating PrPC independently of cell count. 
In order to assess whether hits elicited translational repression or mRNA 
degradation, we assessed steady-state PRNP mRNA levels. RNA was extracted at the 
same 72h time point at which we measured PrPC protein levels, as miRNA-target 
interactions often initially result in translational repression followed by mRNA degradation 
(6). All but three hits were found to down-regulate PRNP mRNA (Fig. S6C). Moreover, the 
degree of mRNA regulation correlated strongly with the degree of protein regulation (R2: 
0.679) for all candidate mimics (Fig. 3), suggesting that the majority of hits function either 
directly via degradation of PRNP mRNA or indirectly via transcriptional regulation. miR-124-
3p, miR-192-3p and miR-299-5p altered PrPC protein but not PRNP mRNA levels, indicating 
that these hits regulate PrPC either by inhibiting/activating PRNP translation directly, or by 
regulating a PrPC interactor.  
 
miRNA Target Sites Abundant in PRNP 3’UTR 
To determine whether the miRNAs identified by our screen regulate PrPC in a direct or 
indirect manner, we examined TargetScan7.2 (www.targetscan.org) predicted miRNA target 
sites within the PRNP 3’UTR (Tab.1). Of the 13 predicted miRNAs with broadly conserved 
sites, three miRNAs, namely miR-148a-3p, miR-148b-3p, miR-152-3p were among our hits. 
Additionally, of 447 miRNAs with poorly conserved sites a further nine hits, namely miR-20b-
5p, miR-188-3p, miR-338-5p, miR-519d-3p, miR-4686, miR-5588-3p, miR-193a-3p, miR-
193b-3p, miR-519b-3p were predicted to bind the PRNP 3’UTR. Two screening hits, namely 
miR-371a-3p and miR-376b-3p, that were not predicted to harbor binding sites in the 3’UTR, 
did however have closely related family members miR-371b-3p and miR-376c-3p that were 
predicted to possess poorly conserved target sites therein. Interestingly, none of the miRNAs 
that induced discordant changes in steady state mRNA and PrPC protein levels had a 
predicted binding site in the PRNP 3’UTR. We further examined CLIP datasets for putative 
miRNA binding sites of all hits (Tab.1). These further confirmed the absence of target sites 
for either miR-124-3p or miR-192-3p, but indicated binding of miR-299-5p to the PRNP CDS. 
Overall 14 miRNAs are predicted to bind the PRNP 3’UTR by targeting 9 sequences.   
In order to confirm putative miRNA target sites and validate a miRNA-mediated 
regulation of protein expression through these sites, we utilized a common dual-luciferase 
reporter assay. The wild type (wt) or mutant 3’UTR or wt CDS of PRNP was cloned 
downstream of the Firefly luciferase CDS. After normalization with Renilla luciferase, which 
acts as an internal control, the Firefly luciferase signal acts as a proxy for miRNA function. 
Plasmids harboring the full-length wt PRNP 3’UTR, 9 mutant forms thereof (Tab.S1), or the 
full-length PRNP CDS were co-transfected into HEK-293T with respective mimics.  
miR-148a-3p, miR-148b-3p and miR-152-3p, only had a minor or no significant effect on 
the wt PRNP 3’UTR reporter (Fig.  4), despite CLIP data indicating that these miRNAs bind 
the PRNP 3’UTR (3, 9). However, when co-transfecting these mimics with their respective 
mutant reporter, we observed significant signal increases relative to the wt 3’UTR reporter. 
Differences in wt and mutant reporters were only observed in the presence of mimics, 
suggesting that these three miRNA directly regulate the PRNP 3’UTR. Notably, sequence 
alignment using Clustal Omega (www.ebi.ac.uk) revealed that all three of these miRNAs are 
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partially complementary to the Renilla luciferase CDS, potentially accounting for the lack of 
effect observed in the wt PRNP 3’UTR reporter. miR-20b-5p, miR-188-3p, miR-338-5p, miR-
371a-3p, miR-519d-3p, miR-519b-3p, miR-4686, miR-193a-3p, miR-193b-3p and miR-5588-
3p all elicited a significant signal reduction when co-transfected with the wt PRNP 3’UTR 
reporter. Moreover, these effects were mitigated when the wt 3’UTR construct was replaced 
with respective mutant reporters for all but miR-5588-3p, thereby confirming that 12 out of 
the 14 predicted sites are functional targets for miRNA-mediated PrPC down-regulation. It is 
feasible that the miR-5588-3p-induced effect could not be inhibited when co-transfecting this 
mimic with its mutant reporter construct due to an additional unpredicted 3’UTR target site. 
Although miR-371a-3p and miR-376b-3p were only derivatively predicted to bind the 
PRNP 3’UTR, we assessed whether they could evoke an effect via the wt 3’UTR reporter. 
We found that miR-371a-3p significantly regulated the PRNP 3’UTR reporter in a site-
specific manner, whereas miR-376b-3p had no effect. The lack of miR-376b-3p-mediated 
regulation may be due to its altered seed region sequence relative to miR-376c-3p, which 
was predicted to bind the PRNP 3’UTR. We also examined whether miR-124-3p, miR-192-
3p or miR-299-5p could elicit an effect via either the PRNP 3’UTR or the CDS, but found that 
none of these mimics significantly regulated either the wt 3’UTR or CDS reporter (Fig. 4). In 
conclusion, our reporter assays revealed that 13 out of the 17 screening hits had functional 
target sites within the PRNP 3’UTR, while the remaining 4 PrPC regulators could not be 
confirmed to regulate PRNP in a direct manner (summarized in Tab.2).  
 
DISCUSSION 
The current study exhaustively explores and validates functional roles of PrPc-regulating 
miRNAs. This was accomplished by developing a robust high-throughput arrayed screening 
platform that assessed direct and indirect effects of the human miRNAome on PrPc levels. 
Selection of a suitable cell line that produces reproducible results, as revealed by control-
derived Z’-Factors, is a prerequisite for successful screening. We detected 17 high-
confidence miRNA mimic hits, 13 of which were found to function directly by binding to the 
PRNP 3’UTR and induce transcript degradation. Crucially, the degree to which miRNA 
mimics regulated PrPC protein correlated well (R2: 0.679) with the degree of PRNP mRNA 
expression change (Fig. 3). These results are consistent with the observation that 66 to 90% 
miRNA-mediated repression can be attributed to mRNA destabilization (15).  
Hit-induced PrPC reduction found in U-251 MG and CHP-212 was not generally reflected 
in SH-SY5Y M4 cells (Tab.2). This was expected for miRNAs acting through the PRNP 
3’UTR, which is not present in SH-SY5Y M4. An exception were miR-193a-3p and miR-
193b-3p, which displayed decreased PrPC levels in all three cell lines. This suggests that 
these miRNAs may induce PrPC regulation through multiple pathways. 
Four of our hits could not be confirmed to regulate PRNP via its 3’UTR or CDS and were 
therefore deemed indirect regulators of PrPC expression. Owing to the high number of 
miRNA targets that may function as single intermediary interactors or in complex regulatory 
cascades, it would be challenging to identify such indirect regulatory pathways. However, 
based on the unchanged PRNP mRNA but significantly altered PrPC protein levels upon 
transfection with miR-124-3p, miR-192-3p or miR-299-5p mimics, we speculate that these 
three miRNAs may function by regulating PrPC protein stability and/or turnover. Conversely, 
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miR-376b-3p, which was found to decrease both mRNA and protein levels, may possibly 
function by targeting a PRNP-regulating transcription factor. 
As PrPc is essential for scrapie-induced neurotoxicity (10), and the depletion of neuronal 
PrPc is known to prevent disease and reverse accompanying pathognomonic spongiosis 
occurring during prion infection (28), reduction or depletion of endogenous PrPc might 
constitute a therapeutic option for TSEs. Moreover, as conditional post-natal knockout (29) 
or complete ablation (34) of PrPC results in relatively mild phenotypes (2, 11), the modulation 
of PrPc levels does in fact represent a compelling therapeutic approach. Notably, the 
pleiotropic nature of miRNAs provides them with one important therapeutic advantage over 
siRNAs, as it enables single miRNAs to modulate multiple possibly disease-linked pathways 
in complex multigenic conditions.  
Applying miRNA functional information to expression datasets has the potential to 
uncover novel miRNA-regulated pathways that may play important, if not causal, roles in 
disease. miR-124-3p, one of the most abundant miRNAs in the brain, is known to be 
deregulated in multiple CNS disorders (44). In prion disease specifically, miR-124-3p has 
been shown to become significantly upregulated in mouse hippocampal CA1 neurons at 70 
and 90 days post scrapie infection, while contrarily becoming downregulated at 130 and 160 
days post infection (27). In human post-mortem sCJD frontal cortical and cerebellar 
samples, miR-124-3p was similarly found to be decreased relative to control tissues (23). 
This conserved temporal regulation in miR-124-3p expression indicates a potential role of 
this miRNA in prion disease pathology. 
Both miR-148a-3p and 148b-3p are highly expressed in the human brain (35). These two 
mimic hits elicited the strongest down-regulatory effect on PrPC protein and PRNP mRNA 
levels (Fig. 3), indicating that these miRNAs may mediate endogenous suppression of the 
prion protein in healthy brains. However, neither of these miRNAs has been found to be 
deregulated during prion infection. 
The current study marks the first to discover a functional indirect regulatory role of miR-
124-3p on PrPC expression levels. No other screening hit except for miR-124-3p has been 
documented as being consistently altered during prion disease. miR-146a-5p and miR-342-
3p, which have been found to be deregulated in multiple TSEs (25, 33, 40, 41), had no effect 
on PrPC expression levels. 
There is a growing consensus that modulation of PrPC may represent the most realistic 
therapeutic approach for treatment of prion diseases, which may have particular prophylactic 
value for genetic PRNP mutation carriers (32). Furthermore, as the depletion of PrPC has 
been found to cause demyelination in the peripheral nervous system (11) through reduced 
excitation of its receptor Gpr126 (20), these considerations highlight the importance of 
elucidating PrPC-regulatory mechanisms in physiological conditions. In-depth investigations, 
not only of animal models but also observational studies in human cohorts are warranted. 
The ultimate goal of such studies would be to test whether manipulation of the miRNA 
landscape, or its downstream effectors in the case of indirectly acting miRNAs, might be 
pharmacologically exploitable for the treatment of patients at risk of prion diseases. 
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Tables 
 
Table 1. TargetScan7.2 predicted target sites of mimic candidates with PRNP 3‘UTR. Units 
in brackets indicate the number of predicted interaction sites when using poorly conserved 
miRNA family criteria. CLIP detected miRNA-PRNP interactions and their respective target 
sites in PRNP transcript (Ensembl ID:ENST00000379440.8) are also illustrated. 
Underscores indicate binding to the CDS and bold lettering indicates a closely related 
miRNA family member. Blue and red fonts represent CHP-212 and SH-SY5Y M4 overlaps 
with U-251 MG screen respectively. 
 
Table 2. Compilation of hit-mediated effects. Heat map of SSMD scores in U-251 MG 
(column 1), CHP-212 (column 2) and SH-SY5Y M4 (column 3) screens. Cell viability and 
PRNP mRNA values are coded according to a ≥10% increase (green arrow), ≥10% 
decrease (red arrow) or no change above / below ≤10% (yellow bar) relative to negative 
controls. Reporter-confirmed target sites and presumptive modes of miRNA action on PrPC 
are also listed. Blue and red fonts represent CHP-212 and SH-SY5Y M4 overlaps with U-251 
MG screen respectively. 
 
FIGURE LEGENDS 
Figure 1. Design of screening strategy and quality controls. A) Screening workflow 
comprises reformatting library, positive controls (light grey) and negative controls (dark grey) 
into 384-well plates, reverse transfecting cells, incubating plates for 72h, removing culture 
media, lysing content, dispensing fluorophore-coupled antibodies and performing a TR-
FRET readout. B) Histograms displaying positive and negative control signal occurrences 
(22 each per plate across 24 plates) for U-251 MG (Z‘: 0.453), CHP-212 (Z‘: -0.403) and SH-
SY5Y M4 (Z‘: 0.072) mimic screens with illustrations of each respectively expressed 
transcript. 
 
Figure 2. miRNA mimic screening identified 19 candidate hits. A) Dual-flashlight plots 
displaying SSMD versus Log2 fold change (FC) with illustrations of each respectively 
expressed PRNP / Prnp transcript for U-251 MG (black), CHP-212 (blue) and SH-SY5Y M4 
(red) screens. Sample distribution angles illustrated in plots indicate cell-line dependent 
variability in PrPC expression, with U-251 MG exhibiting stronger sample replicability, 
exemplified by high SSMDs, and CHP-212 exhibiting larger biological effect sizes, as 
illustrated by greater Log2 fold changes. B) SSMD overlaps between U-251 MG (SSMD ≥5, 
≤-5) and CHP-212 (≥3, ≤-3) (left plot) identified 12 candidates (blue crosses). SSMD 
overlaps between U-251 MG (≥3, ≤-3) and M4 (≥3, ≤-3) (right plot) identified 7 candidates 
(red crosses). A majority of candidates displayed consistent miRNA-induced down- or 
upregulation in overlapped screens, whereas three hits exhibited divergent PrPC regulation. 
(Bottom right quadrant of left plot: 1 blue cross. Top left quadrant of right plot: 1 blue and 1 
red cross). C) SSMD overlaps between CHP-212 (≥3, ≤-3) and SH-SY5Y M4 (≥3, ≤-3) 
shows comparative distribution of mimic candidates. 
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Figure 3. Relationship between expression of PRNP mRNA and PrPC protein in cells treated 
with miRNA mimics. Correlation coefficient of the linear regression analysis between PrPC 
protein (N=3, SEM error bars) and steady state PRNP mRNA (N=3, SEM error bars) was R2: 
0.679 with 95% confidence intervals. This suggests that miRNA mimic-driven regulation of 
PrPC results from degradation of the PRNP transcript. Blue crosses represent CHP-212, 
while red crosses represent SH-SY5Y M4 screen overlaps. Axis values indicate changes in 
expression relative to respective controls. 
  
Figure 4. Reporter assay confirms predicted PRNP 3’UTR sites as targets for majority of 
hits. A) Co-transfection of mimics with wt PRNP 3’UTR or respective mutation harboring 
reporters found that 12 out of 14 TargetScan7.2 predictions were functional sites for 
miRNAs. Only miR-376b-3p did not significantly regulate Firefly luciferase via the 3’UTR and 
only miR-5588-3p could not be confirmed to elicit its effect through its prospective target site. 
B) Assessment of miR-124-3p, 192-3p and 299-5p with wt PRNP 3’UTR or CDS reporters 
found that none of these miRNAs significantly regulated Firefly luciferase through either site. 
 
 
Supplementary Materials 
Supplementary Table S1. Putative target site mutations in reporters. TargetScan7.2 
predicted interaction sites of screening hits with 3‘UTR of PRNP (Ensembl ID: 
ENST00000379440.8). wt target and mutated target sequences in reporter constructs are 
listed. Bold lettering represents a related miRNA family member and red font indicates 
altered nucleotides in reporter. Blue and red font indicate CHP-212 and SH-SY5Y M4 
overlaps with U-251 MG screen respectively. 
 
Supplementary Table S2. Complete miRNA mimic screening datasets in U-251 MG, CHP-
212 and SH-SY5Y M4. Tables show sample ID, replicate Net FRET signals, Net FRET 
signal mean, Net FRET signal SD, sample SSMD, log2 fold change, P-values, miRNA 
accession numbers, corresponding mature miRNA name, and mature miRNA sequence. 
 
Supplementary Table S3. Complete miRNA inhibitor screening datasets in U-251 MG and 
CHP-212. Tables show sample ID, replicate Net FRET signals, Net FRET signal mean, Net 
FRET signal SD, sample SSMD, log2 fold change, P-values, target miRNA accession 
numbers, target miRNA name, and target miRNA sequence. 
 
Supplementary Figure S1. SH-SY5Y PRNP-/- clone sequencing report. Sanger sequencing 
trace data shows a deletion of the second adenine in the third codon of the PRNP CDS 
(chr20: 4,699,229), in exon 2 (Ensembl ID:ENST00000379440.8) in SH-SY5Y PRNP-/- clone. 
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Supplementary Figure S2. High miRNA mimic screening replicability. A) Western blot PrPC 
expression in 30µg of cell lysates (10µg for SH-SY5Y M4). B) TR-FRET PrPC expression in 
6µg cell lysates (N=4, SD error bars) using POM2-Eu and POM1-APC fluorophores. C) 
Linear correlation with 95% confidence intervals of biological replicates in U-251 MG, CHP-
212 and SH-SY5Y M4 mimic screens with illustrations of respectively expressed transcripts. 
Supplementary Figure S3. TR-FRET in culture media versus media-removed conditions. 
Various numbers of SH-SY5Y M4 cells seeded per well in 30uL media and incubated for 72 
hours prior to direct addition of 10uL 4X lysis buffer (left plot) or media removal followed by 
addition of 10uL 1X lysis buffer (right plot). PrPC assessment via TR-FRET shows reduced 
replicate variability when applying a media removal step prior to lysis (N=48, SD error bars).  
 
Supplementary Figure S4. No linear correlation between miRNA inhibitor screen replicates. 
A) Assessing efficacy of the miRNA inhibitor library by transfecting an inhibitor of let-7d-5p, a 
ubiquitously expressed miRNA known to negatively regulate HMGA2 levels, into U-251 MG 
cells at 20, 40 and 60nM. RT-qPCR analysis of HMGA2 normalized to ACTB was performed 
for let-7d-5p mimic, let-7d-5p inhibitor and non-targeting siRNA (Neg Ctrl) -transfected cells 
(N=3, SEM error bars). A 60nM concentration of miRNA inhibitors was selected for 
screening in both U-251 MG and CHP-212 cells. B) Histograms displaying positive and 
negative control signal occurrences (22 per plate across 24 plates) for U-251 MG (Z‘: 0.396) 
and CHP-212 (Z‘: -0.346) inhibitor screens with illustrations of each respectively expressed 
transcript. C) Biological triplicate with linear regressions and 95% confidence intervals in U-
251 MG and CHP-212 inhibitor screens display a clustering of sample replicates, indicating 
an overall lack of biological effect produced by the inhibitor library. 
 
Supplementary Figure S5. Inhibitor screens identify no hits. A) Dual-flashlight plots 
displaying SSMD versus Log2 fold change (FC) in U-251 MG and CHP-212 miRNA inhibitor 
screens with illustrations of expressed transcripts. B) SSMD inhibitor screen overlaps 
identify 0 hits at low cut-off criteria among U-251 MG (SSMD ≥1.5, ≤-1.5) and CHP-212 
(≥1.5, ≤-1.5). 
 
Supplementary Figure S6. Hit-induced effects. A) PrPC protein regulation by hits in U-251 
MG mimic screen (TR-FRET) normalized to respective controls. B) Cell viability alterations 
by mimic hits in U-251 MG (CellTiter-Glo2.0) normalized to respective controls. Protein 
regulation coinciding with 10% increased or decreased viability were excluded. C) PRNP 
mRNA regulation by hits in U-251 MG (RT-qPCR using ACTB, TBP and GUSB 
housekeeping genes) normalized to respective controls. Blue and red crosses indicate CHP-
212 and SH-SY5Y M4 overlaps with U-251 MG screen respectively. 
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